Search

Search results

1. New review rules—the impact on drug access in Canada

   In 2017, the federal government introduced new regulations for the drug review board. ...

2. Delayed drug approvals in Canada—here’s why

   New drugs are approved later in Canada than in the United States and European Union. ...

3. Approving new drugs in Canada—a 30-year review

   Regardless of their potential impact on patient health, drug approval times in Canada were longer than in other countries. ...

4. Is Ottawa competent enough to design an efficient and effective national pharmacare program?

   A national formulary—essentially a list of drugs—is unlikely to match the comprehensive lists covered by private insurance plans. ...

5. Pharmacare ‘cost-savings’ should not trump appropriate drug use

   The final report of the Advisory Council on the Implementation of National Pharmacare, due in spring 2019, is meant to provide the federal government with recommendations on how best to implement a national drug insurance program. Despite ...

6. Under OHIP+, access to new or innovative drugs for rare disorders is limited

   The Ontario government has launched its much promoted, publicly-funded pharmacare program called OHIP+, which will provide cost-free access to all prescription drugs in the Ontario formulary for the province’s four million children and ...

7. ‘Transparent’ campaign promise should apply to drug reaction reporting in Canada

   Spontaneous adverse drug reaction (ADR) reporting systems are under-utilized worldwide and Canada’s is no exception. However, apart from expensive unique arrangements such as patient registries, they are the only systems regularly ...

8. Improvements in health-care services must accompany any increase in federal money

   Provincial and territorial health ministers met recently in Toronto to discuss “several key areas” including the affordability and accessibility of pharmaceutical drugs. Dr. Eric Hoskins, Ontario's minister of health and long-term ...